Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded ...

Pfizer's (NYSE: PFE) management team is confident in its 2025 opportunities. Where to invest $1,000 right now? Our analyst ...

Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on.

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

The stock's fall snapped a four-day winning streak.

Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) ...

It operates through three segments: Outdoor, Active, and Work. The company offers High performance outdoor apparel, footwear, equipment, accessories; outdoor, adventure-inspired lifestyle footwear ...

Pfizer and Allergan have confirmed that they will merge in a $160 billion deal, with Ireland-domiciled Allergan acquiring the US pharma giant, and re-naming itself Pfizer. The deal is the biggest ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...